8 results about "CDC42" patented technology

The invention discloses a construction method of an endothelial cell knockout Cdc42 gene aggravated bleomycin induced pulmonary fibrosis mouse model, which comprises the following steps of: mating a Cdc42 gene conditional knockout mouse with a mouse (Tie2-CreER) of which the endothelial cell specifically expresses tamoxifen induced Cre recombinase to obtain a double-transgenic mouse (Cdc42fl / fl-Tie2-CreER); the Cdc42 gene is specifically knocked out in vascular endothelial cells under the induction of tamoxifen, and then pulmonary fibrosis is induced by subcutaneous injection of bleomycin. The model shows aggravated pulmonary fibrosis phenotypes, including collagen deposition increase, alveolar structure damage and fibrosis-related protein expression up-regulation, and is high in construction success rate and good in repeatability. The invention also provides an application of the model in research of systemic sclerosis related interstitial lung disease pathogenesis and screening of anti-pulmonary fibrosis drugs, and an application of the Cdc42 gene as a drug target, and provides an accurate and reliable tool for pulmonary fibrosis research.

The present invention relates to a bivalent, bispecific monoclonal antibody (bbmAb) or a variant thereof for use in treating or alleviating symptoms of autoinflammatory or disease-related conditions in subjects requiring such treatment or elimination of CDC42 mutations or XIAP deficiency.

An inhibitor of the Rho GTPase Cdc42 is proposed for use in the prevention and / or treatment of Parkinson's disease in humans or animals. In a mouse model where the mice were genetically modified to accumulate α-synuclein and develop Parkinson's disease, administration of a Cdc42 inhibitor to the affected mice reduced α-synuclein accumulation, improved Parkinson's disease symptoms, increased mean lifespan, and extended overall lifespan. Minimal to no adverse effects were observed in the affected mice.

The invention discloses a fusarium venanii strain with high substrate conversion rate and low RNA (Ribonucleic Acid) content and application of the fusarium venanii strain, and belongs to the fields of genetic engineering technology and food biotechnology. Compared with a wild strain, the fusarium venanii Fcdc has the advantages that the conversion rate of a gene Cdc42 on a genome from a substrate to thallus is increased to 67.06%, the conversion rate from the substrate to protein is increased to 26.01%, the sugar consumption for producing mycelia with the same dry weight is reduced by 60%-70%, the sugar consumption for producing mycelia protein with the same dry weight is reduced by 60%-70% compared with the wild strain, and the RNA content of the mycelia is reduced by more than 90% and is as low as 0.32% compared with the wild strain; the method has the advantages that the method is simple and convenient to operate, a heat treatment and nucleic acid removal step is not needed, the production efficiency and the safety quality of the fusarium venanii hypha protein are obviously improved, the production cost is reduced, and the fusarium venanii can be used for further developing genetic engineering modification work and cultivating fusarium venanii strains with high protein content and low RNA content.

The invention relates to an inhibitor of Rho GTPase Cdc42 for use in the prevention and / or treatment of Parkinson's disease of the human or animal body. In a mouse model in which the mice were genetically modified to accumulate α-synuclein and develop Parkinson's disease, it has been shown that the administration of a Cdc42 inhibitor in the diseased mice reduces the accumulation of α-synuclein, improves the symptoms of Parkinson's disease, increases the average life expectancy, and prolongs the total life span. Only minimal to no side effects occurred in the diseased mice.

The present invention relates to a bivalent bispecific monoclonal antibody (bbmAb), or a variant thereof, for use in treating or alleviating symptoms of a self-inflammation or disease based on CDC42 mutation or XIAP deficiency in a subject in need thereof.

The application discloses a strain of Fusarium venenatum with high substrate conversion rate and low RNA content and an application thereof, and belongs to the field of genetic engineering technology and food biotechnology. Cdc42 Compared with the wild type, the Fusarium venenatum Fcdc has the following advantages: the substrate conversion rate is increased to 67.06%, the substrate to protein conversion rate is increased to 26.01%, the sugar consumption for producing the same dry weight of mycelium is reduced by 60%-70%, the sugar consumption for producing the same dry weight of mycelium protein is reduced by 60%-70% compared with the wild type, the RNA content of the mycelium is reduced by more than 90% compared with the wild type strain, is as low as 0.32%, and the step of removing nucleic acid by heat treatment is not needed, so that the production efficiency and safety quality of the mycelium protein of the Fusarium venenatum are significantly improved, the production cost is reduced, the Fusarium venenatum can be further used for genetic engineering modification work, and a Fusarium venenatum strain with high protein content and low RNA content is cultivated.